Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: Role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082

Diabetes Care

Volumn 36, Issue 1, 2013, Pages

  DeVries, J Hans ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; SITAGLIPTIN; VILDAGLIPTIN;

BLOOD GLUCOSE MONITORING; DRUG EFFICACY; GLUCOSE ASSAY; GLUCOSE BLOOD LEVEL; GLUCOSE OXIDATION; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; INHIBITION KINETICS; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS;

ADAMANTANE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; MALE; NITRILES; PYRAZINES; PYRROLIDINES; TRIAZOLES;

EID: 84872050584     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1218     Document Type: Letter

References (2)

1. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082
2. Siegelaar SE, Kerr L, Jacober SJ, Devries JH. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care 2011;34:855-857